APA (7th ed.) Citation

JE, L., H, H., S, D., D, L., J, L., B, B., . . . AJ, R. (2023). Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 77(2), 186. https://doi.org/10.1093/cid/ciad187

Chicago Style (17th ed.) Citation

JE, Levitt, et al. "Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 77, no. 2 (2023): 186. https://doi.org/10.1093/cid/ciad187.

MLA (9th ed.) Citation

JE, Levitt, et al. "Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 77, no. 2, 2023, p. 186, https://doi.org/10.1093/cid/ciad187.